{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:21:23Z","timestamp":1770506483822,"version":"3.49.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1097\/wnf.0b013e318154c7c4","type":"journal-article","created":{"date-parts":[[2009,3,4]],"date-time":"2009-03-04T23:16:26Z","timestamp":1236208586000},"page":"256-265","source":"Crossref","is-referenced-by-count":48,"title":["Overnight Switch From Oral Dopaminergic Agonists to Transdermal Rotigotine Patch in Subjects With Parkinson Disease"],"prefix":"10.1097","volume":"30","author":[{"given":"Peter A.","family":"LeWitt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babak","family":"Boroojerdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"MacMahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Patton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Jankovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-2-20210203","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/mds.20202","article-title":"New concerns about old drugs: Valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance.","volume":"19","author":"Rascol","year":"2004","journal-title":"Mov Disord"},{"key":"R3-2-20210203","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/jnnp.51.4.529","article-title":"Parkinson's disease: an open label trial of pergolide in patients failing bromocriptine therapy.","volume":"51","author":"Factor","year":"1988","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R4-2-20210203","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1212\/WNL.52.6.1227","article-title":"Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow?","volume":"52","author":"Goetz","year":"1999","journal-title":"Neurology"},{"key":"R5-2-20210203","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s007020050212","article-title":"An overnight switch to ropinirole therapy in patients with Parkinson's disease. Short communication.","volume":"106","author":"Canesi","year":"1999","journal-title":"J Neural Transm"},{"key":"R6-2-20210203","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2125.1980.tb04795.x","article-title":"Cross tolerance between two dopaminergic ergot derivatives-bromocriptine and lergotrile.","volume":"9","author":"Teychenne","year":"1980","journal-title":"Br J Clin Pharmacol"},{"key":"R7-2-20210203","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00702-004-0110-6","article-title":"Usefulness of switching to cabergoline from other dopamine agonists in patients with advanced Parkinson's disease.","volume":"111","author":"Shiraishi","year":"2004","journal-title":"J Neural Transm"},{"key":"R8-2-20210203","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/00002826-200111000-00006","article-title":"Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: open label pilot responses to three different dose-ratios.","volume":"24","author":"Gimenez-Roldan","year":"2001","journal-title":"Clin Neuropharmacol"},{"key":"R9-2-20210203","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s007020170097","article-title":"Switching from pergolide to pramipexole in patients with Parkinson's disease.","volume":"108","author":"Hanna","year":"2001","journal-title":"J Neural Transm"},{"key":"R10-2-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clinthera.2005.12.003","article-title":"Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease: a review of the literature.","volume":"28","author":"Thobois","year":"2006","journal-title":"Clin Ther"},{"key":"R11-2-20210203","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00415-004-0328-0","article-title":"Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.","volume":"251","author":"Linazasoro","year":"2004","journal-title":"J Neurol"},{"key":"R12-2-20210203","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/mds.20210","article-title":"Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.","volume":"19","author":"Grosset","year":"2004","journal-title":"Mov Disord"},{"key":"R13-2-20210203","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s00702-003-0081-z","article-title":"Switching and combining dopamine agonists.","volume":"110","author":"Reichmann","year":"2003","journal-title":"J Neural Transm"},{"key":"R14-2-20210203","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/mds.870090204","article-title":"N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease.","volume":"9","author":"Belluzzi","year":"1994","journal-title":"Mov Disord"},{"key":"R15-2-20210203","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0361-9230(96)00346-2","article-title":"Selective full dopamine D1-like (SKF-82958) and D2-like (N-0923) agonist combination in the MPTP monkey model of hemiparkinsonism.","volume":"43","author":"Domino","year":"1997","journal-title":"Brain Res Bull"},{"issue":"suppl 1","key":"R16-2-20210203","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1212\/WNL.65.2_suppl_1.S3","article-title":"A novel dopamine agonist for the transdermal treatment of Parkinson's disease.","volume":"65","author":"Jenner","year":"2005","journal-title":"Neurology"},{"key":"R17-2-20210203","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/01.wnf.0000162228.00154.ba","article-title":"Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease.","volume":"28","author":"Guldenpfennig","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"R18-2-20210203","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2165\/00023210-200519110-00006","article-title":"Rotigotine in Parkinson's disease.","volume":"19","author":"Reynolds","year":"2005","journal-title":"CNS Drugs"},{"key":"R19-2-20210203","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00002826-200105000-00008","article-title":"Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease.","volume":"24","author":"Metman","year":"2001","journal-title":"Clin Neuropharmacol"},{"key":"R20-2-20210203","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1212\/01.wnl.0000259516.61938.bb","article-title":"Advanced Parkinson disease treated with rotigotine transdermal system (PREFER Study).","volume":"68","author":"LeWitt","year":"2007","journal-title":"Neurology"},{"key":"R21-2-20210203","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1212\/WNL.65.2_suppl_1.S11","article-title":"Clinical studies with transdermal rotigotine in early Parkinson's disease.","volume":"65","author":"Poewe","year":"2005","journal-title":"Neurology"},{"key":"R22-2-20210203","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/01.WNF.0000228179.83335.65","article-title":"Rotigotine transdermal patch enables rapid titration to effective doses in advanced-stage idiopathic Parkinson disease: subanalysis of a parallel group, open-label, dose-escalation study.","volume":"29","author":"Babic","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"R23-2-20210203","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/archneur.60.12.1721","article-title":"A controlled trial of rotigotine monotherapy in early Parkinson's disease.","volume":"60","year":"2003","journal-title":"Arch Neurol"},{"issue":"suppl 10","key":"R24-2-20210203","first-page":"S93","article-title":"Rotigotine transdermal patch (Neupro) is efficacious and safe in patients with early-stage, idiopathic Parkinson's disease, regardless of gender, age, duration and severity of disease. Results of a multicenter, randomized, double-blind, placebo-controlled trial.","volume":"20","author":"Watts","year":"2005","journal-title":"Mov Disord"},{"key":"R25-2-20210203","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1212\/01.wnl.0000252355.79284.22","article-title":"Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease.","volume":"68","author":"Watts","year":"2007","journal-title":"Neurology"},{"key":"R26-2-20210203","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/mds.1085","article-title":"Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study.","volume":"16","author":"Hutton","year":"2001","journal-title":"Mov Disord"},{"issue":"suppl 2","key":"R27-2-20210203","first-page":"321","article-title":"Rotigotine transdermal patch for 24 hours can improve sleep quality in patients with Parkinson's disease. Report from two open label trials.","volume":"13","author":"Giladi","year":"2006","journal-title":"Eur J Neurol"},{"key":"R28-2-20210203","first-page":"353","article-title":"An analysis of the time-relations of electrocardiograms.","volume":"7","author":"Bazett","year":"1920","journal-title":"Heart"},{"key":"R29-2-20210203","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1212\/01.wnl.0000215250.82576.87","article-title":"Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.","volume":"66","author":"Pahwa","year":"2006","journal-title":"Neurology"},{"key":"R30-2-20210203","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1212\/01.wnl.0000238508.68593.1d","article-title":"Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.","volume":"67","author":"Yamamoto","year":"2006","journal-title":"Neurology"},{"key":"R31-2-20210203","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/mds.20887","article-title":"Valvular heart disease in Parkinson's disease vs. controls: an echocardiographic study.","volume":"21","author":"Peralta","year":"2006","journal-title":"Mov Disord"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00002826-200709000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T01:41:44Z","timestamp":1618278104000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-200709000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e318154c7c4","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}